CEDRA Corporation
, a division of
Worldwide Clinical Trials
,announces its new company name, Worldwide Clinical Trials Drug Development Solutions. This unified name adds to the continuity and full-service offerings our companies collectively provide.
Worldwide Clinical Trials Drug Development Solutions continues to offer Bioanalytical Sciences and Clinical Research Services, as well as specialized studies to determine the effects of dose, formulation, dosing regimen, drug interactions, genotype, gender and other factors on pharmacokinetics.
Worldwide Clinical Trials and Worldwide Clinical Trials Drug Development Solutions will use their combined medical and scientific expertise to provide service in drug development. Worldwide Clinical Trials specializes in mid-/late-phase, and Worldwide Clinical Trials Drug Development Solutions specializes in bioanalytical/early-phase clinical trials, covering all phases in the clinical trials process.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.